Illuminare Biotechnologies reported first‑in‑human Phase 1 data showing Illuminare‑1, a fluorescent agent that binds myelin, enables rapid and sustained intraoperative nerve visualization under blue light. Early results indicate the agent can delineate peripheral nerves from surrounding tissue, potentially reducing iatrogenic nerve injury during procedures. The company presented safety and imaging onset data and outlined plans for broader clinical evaluation. Illuminare‑1 is an imaging probe—these agents are administered systemically or locally and fluoresce under specific wavelengths to aid real‑time surgical decisions. If larger trials confirm reduced nerve injury rates, the technology could affect ophthalmic, head‑and‑neck, urology, and general surgical workflows.